Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Non-Hodgkin's Lymphoma
NCT ID: NCT01282476 (View complete trial on
DFCI Protocol ID: 10-441


Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory studies. However, it is not known if it will show the same activity in humans. Panobinostat has been given to participants with various types of cancers, including DLBCL, in previous research studies. In this study panobinostat will be given with the the antibody rituximab, which is FDA approved to be given with chemotherapy in DLBCL.


Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Dana Farber Cancer Institute at Londonderry, Beth-Israel Deaconess Medical Center

Overall PI:
David C. Fisher, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Jeremy Abramson, MD, Massachusetts General Hospital
Frederick Briccetti, M.D., Dana Farber Cancer Institute at Londonderry Hospital

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Kathleen McDermott,

Eligibility Criteria

Inclusion Criteria: - Relapsed or refractory DLBCL - More than 1 line of prior chemotherapy Exclusion Criteria: - Currently receiving anticancer therapy or investigational agents - Major surgery within last 4 weeks - Known leptomeningeal or brain metastases - Known HIV infection - Uncontrolled fungal, bacterial, viral or other infection - History of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 3 years - Hepatitis B or C positive - GI disease - Pregnant or breastfeeding - Prior treatment with an HDAC inhibitor including valproic acid
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms